We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current FHTX market cap is 222.62M. The company's latest EPS is USD -2.3123 and P/E is -2.27.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 5.31M | 5.6M | 17.48M | 5.77M | 5.05M |
| Operating Income | -33.32M | -32.05M | -17.08M | -30.78M | -28.19M |
| Net Income | -30.49M | -29.49M | -14.35M | -24.11M | -25.02M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 430k | 1.32M | 19.23M | 34.16M |
| Operating Income | -51.08M | -68.53M | -100.73M | -117.14M | -107.91M |
| Net Income | -51.13M | -68.8M | -101.32M | -108.88M | -98.43M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 372.88M | 339.58M | 313.42M | 285.92M | 255M |
| Total Liabilities | 397.47M | 388.93M | 370.81M | 363.11M | 352.49M |
| Total Equity | -24.59M | -49.35M | -57.39M | -77.19M | -97.49M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 22.34M | 255.59M | 519.77M | 404.88M | 285.92M |
| Total Liabilities | 23.81M | 109.41M | 422.9M | 404.77M | 363.11M |
| Total Equity | -88.02M | 146.19M | 96.87M | 112k | -77.19M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.18M | -63.36M | -90.57M | -118.11M | -29.35M |
| Investing | 29.51M | 68.64M | 107.07M | 144.45M | 27.1M |
| Financing | 102k | 205k | 1.59M | 1.78M | 1.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -46.34M | -31.29M | -50.25M | 193.61M | -118.11M |
| Investing | -964k | -108.91M | 36.17M | -244.32M | 144.45M |
| Financing | 23.97M | 217.47M | 22.42M | 1.76M | 1.78M |
| Market Cap | 222.62M |
| Price to Earnings Ratio | -2.27 |
| Price to Sales Ratio | 6.56 |
| Price to Cash Ratio | 2.79 |
| Price to Book Ratio | -2.9 |
| Dividend Yield | - |
| Shares Outstanding | 42.57M |
| Average Volume (1 week) | 75.04k |
| Average Volume (1 Month) | 102.05k |
| 52 Week Change | -40.77% |
| 52 Week High | 9.97 |
| 52 Week Low | 2.70 |
| Spread (Intraday) | 1.13 (17.77%) |
| Company Name | Foghorn Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.foghorntx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
